GSA Capital Partners LLP raised its stake in Altimmune, Inc. (NASDAQ:ALT – Free Report) by 153.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 445,868 shares of the company’s stock after purchasing an additional 269,676 shares during the quarter. GSA Capital […]
B. Riley reissued their buy rating on shares of Altimmune (NASDAQ:ALT – Free Report) in a research note released on Tuesday morning, Benzinga reports. They currently have a $20.00 target price on the stock. A number of other brokerages have also weighed in on ALT. The Goldman Sachs Group started coverage on shares of Altimmune […]
WealthPlan Investment Management LLC purchased a new position in Altimmune, Inc. (NASDAQ:ALT – Free Report) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 11,931 shares of the company’s stock, valued at approximately $31,000. A number of other institutional investors and hedge funds also […]